RONALD S. GO, MD

Plain English
This study focused on a severe blood disorder called immune thrombocytopenia (ITP), where the body destroys its own platelets, leading to dangerously low levels. Researchers treated three patients, aged 39, 58, and 85, who were not helped by standard treatments and had platelet counts below 2,000. After receiving a new therapy called daratumumab, all three patients quickly recovered their platelet counts to normal within just one week, which helped stabilize their health for further medical care. Who this helps: This benefits patients with severe ITP who do not respond to traditional treatments.

Plain English
The study looked at how certain blood markers relate to the risk of developing a condition called AL amyloidosis, which can occur in some patients with blood disorders. The research included nearly 2,000 patients and found that those with higher levels of free light chains (dFLC) and a history of certain blood disorders were at greater risk, with a 10% chance of developing AL amyloidosis within 20 months if their dFLC was above 80 mg/dL. Understanding these risk factors can help doctors monitor patients better and potentially catch AL amyloidosis earlier. Who this helps: This helps patients with blood disorders and their doctors.

Plain English
This study looked at why patients with POEMS syndrome, a rare disorder affecting multiple body systems, die. Out of 89 patients who passed away, researchers found that 32 died due to complications related to POEMS, with 19 of these deaths attributed to a specific condition called capillary leak phenotype (CLP). CLP symptoms included severe swelling and fluid accumulation that led to sudden drops in blood pressure and organ failure, with patients surviving only about 4 months after the onset of CLP. Who this helps: This information is important for doctors treating patients with POEMS syndrome.

Plain English
This study looked at whether a specific training program aimed at improving processing speed could help adults with mild cognitive impairment related to Alzheimer's disease maintain their daily functions over two years. The results showed that the training didn't offer any significant benefits compared to a control group that did regular computer activities, as both groups experienced declines in abilities like driving and daily tasks. The findings highlight that those with more brain degeneration at the start of the study tended to see worse outcomes, emphasizing the impact of brain health on daily functioning. Who this helps: This research benefits patients with mild cognitive impairment and their families by clarifying the effectiveness of cognitive training programs.

Plain English
This research studied a 71-year-old man who developed anemia and other symptoms after being infected by a tick-borne parasite called Babesia microti. Despite taking standard treatments, his condition didn’t improve until he was given high-dose prednisone, which helped his blood levels recover. This case highlights the importance of doctors recognizing that babesia infections can cause a specific type of anemia so they can treat patients more effectively. Who this helps: This finding helps patients with tick-borne infections and their doctors.

Plain English
This research reviewed how machine learning (ML) can predict outcomes for patients undergoing a specific heart procedure called percutaneous coronary intervention (PCI). The review looked at data from over 4.9 million patients across 11 studies and found that while ML models were generally accurate, there were issues with how missing patient data was handled and with validating these models against real-world situations. This is important because reliable predictions can improve patient outcomes, though the challenges must be solved before these tools can be widely used in hospitals. Who this helps: This helps doctors and healthcare providers in making better decisions for heart patients.

Plain English
This study looked at a 25-year-old man with H syndrome, which caused him to develop problematic growths on his brain and spine. Genetic testing identified a specific mutation linked to his condition, and after treatment with the drug cobimetinib, he showed significant improvement in his symptoms within a month. This research highlights a new treatment option that can help manage serious neurological complications in patients with this rare genetic disorder. Who this helps: Patients with H syndrome and related neurological symptoms.

Plain English
Researchers studied a new type of laser called a Quantum Cascade Laser, specifically focusing on a design that makes the laser beam more concentrated and powerful while still maintaining quality. They found that a new design with a wide 200-micrometer laser was able to produce a beam with a sharper focus—a divergence angle of just 2.5 degrees—while achieving 30% higher peak power compared to traditional designs. This matters because it could lead to more efficient lasers that are easier to fabricate, which can be used in various applications like medical imaging and environmental sensing. Who this helps: This benefits engineers and scientists working on advanced laser technologies.

Plain English
This study looked at how replacing fibrinogen, a protein that helps blood clot, affects bleeding and survival in patients undergoing thoracic aortic surgery. It found that patients with low fibrinogen levels (below 150 mg/dL) who received fibrinogen replacement had significantly less major bleeding (49.7%) compared to those who didn’t receive it (74.6%). However, there was no difference in the need for surgery to stop bleeding or in mortality rates one year later between the two groups. Who this helps: This research benefits patients with low fibrinogen levels undergoing thoracic aortic surgery.

Plain English
This study looked at a rare condition called VEXAS syndrome, which is marked by severe inflammation and blood problems. Researchers analyzed 80 patients and found that mutations in the UBA1 gene were common, occurring in 75% of cases, and that over half of the patients also had other gene mutations related to blood disorders, although these did not affect inflammation levels. The findings indicate that VEXAS syndrome is different from typical blood cancers, leading to a survival rate of only 60% after 10 years for affected individuals, especially those with anemia or low platelet counts. Who this helps: This helps patients with VEXAS syndrome and their doctors understand disease progression and treatment options.

Plain English
This study looked at two patients with a rare tumor called epithelioid hemangioendothelioma (EHE) in their lower legs. One patient was initially treated with surgery but had two relapses, which were then treated with radiation; the other patient received radiation therapy right from the start. These cases highlight that radiation therapy can be an important treatment option for EHE when surgery alone isn't enough. Who this helps: This information is beneficial for patients with EHE and their doctors.

Plain English
This study looked at how well a new antibiotic called cefiderocol works in treating infections caused by hard-to-treat bacteria. Researchers found that, out of 22 patients, the death rate was 13.6% within 28 days, but it was 0% for those with bloodstream or urinary tract infections, and 16.7% for those with lung infections. When cefiderocol was used with another antibiotic, no patients died, while the death rate was 25% for those who only received cefiderocol. Who this helps: This research benefits doctors treating patients with infections from resistant bacteria.

Plain English
This study looked at how much Medicare spent on cancer drugs that were wasted between 2017 and 2020, finding that about $590 million worth of these drugs went unused each year. A specific set of policies, called the Infrastructure Investment and Jobs Act (IIJA), could have saved an estimated $172 million and potentially allowed treatment for an additional 18,289 patients by redistributing the wasted drugs. This research is important because it highlights how better drug management can reduce costs and help more patients get the treatments they need. Who this helps: Patients with cancer who might benefit from better access to treatments.

Plain English
This study tested a new training tool that helps doctors in training learn how to decide if organs are suitable for transplantation based on infection risks. Trainees participated in a simulation where they assessed the suitability of organs, and 87% of them believed the simulation effectively taught them this skill. The training improved their decision-making, as shown by an increase in correct responses after the exercise, highlighting the importance of practice in preparing them for real-life scenarios. Who this helps: This benefits medical trainees and ultimately improves patient care in organ transplantation.

Plain English
This study investigated how specific areas of the brain are involved in processing attention across different types of tasks involving space and sensory experiences. Researchers scanned the brains of 20 participants and found that the frontoparietal network (FPN) plays a key role in modulating attention but the activation in this network changes depending on the type of sensory information being focused on. They discovered that there are distinct brain regions that respond differently depending on what kind of attention is required. Who this helps: This helps researchers and clinicians understand how attention works in the brain, which can improve treatments for attention-related disorders.

Plain English
This study identified three new orchid species in Malaysia: Paphiopedilum exul, Calanthe chrysoglossoides, and Luisia brachystachys. It also documented three rare species—Bryobium cordiferum subsp. borneense, Habenaria rostellifera, and Taeniophyllum rugulosum—from different regions of Malaysia. By providing clear descriptions and photos, this research makes it easier for conservationists and botanists to identify and understand these rare plants, which is important for their preservation. Who this helps: This helps conservationists and botanists working to protect rare orchid species.

Plain English
This study looked at how the brain reacts to different types of touch sensations, particularly focusing on the timing and structure of those sensations. Researchers found that continuous touch led to a stronger brain response compared to touches that were spaced out, and longer touches produced an even bigger response. Understanding these differences is important because it can improve the design and analysis of brain imaging studies that explore how we process touch sensations. Who this helps: This helps researchers and doctors studying sensory processing and designing treatments for sensory disorders.

Plain English
This study looked at how quickly people with mild cognitive impairment (MCI) think and how that affects their ability to perform daily tasks like driving and managing finances. Researchers found that faster cognitive processing speed is linked to better performance in these areas, with a strong relationship showing that improvements in processing speed significantly enhance daily living activities (p < .001), mobility (p < .001), and driving skills (p = .002). Understanding this connection is essential because it can help identify which patients may struggle with daily tasks, allowing for targeted support and interventions. Who this helps: This helps patients with mild cognitive impairment and their caregivers.

Plain English
This study looked at how different ways of giving bortezomib, a drug used in combination with lenalidomide and dexamethasone to treat multiple myeloma, affected patients' outcomes. Researchers analyzed data from 555 newly diagnosed patients and found that although patients treated with bortezomib twice a week had quicker responses, they experienced more nerve pain. In contrast, those who received it once a week had slightly better response rates, but overall, there was no significant difference in long-term survival or progression of the disease among the different schedules. Who this helps: This helps patients with multiple myeloma by providing insights into the best treatment schedules.

Plain English
This study looked at patients with severe COVID-19 pneumonia who needed a ventilator and were treated with a drug called tocilizumab. Out of 115 patients analyzed, those on tocilizumab had a slightly lower average of other health issues compared to those not on the drug, but there was no significant difference in the survival rates after 30 days—both groups had high mortality. This matters because it indicates that tocilizumab might not be as effective as hoped for improving outcomes in these critically ill patients. Who this helps: Patients with severe COVID-19 pneumonia and their healthcare providers.

Plain English
This study examined the effects of high-titer convalescent plasma (CCP) on patients with COVID-19 pneumonia. Out of 51 patients treated, those not on breathing machines had a low intubation rate of 13.9% and a high survival rate of 88.9% after 30 days. The treatment also helped patients produce their own antibodies against the virus while being safe, with only one mild rash noted as a side effect. Who this helps: This benefits COVID-19 patients, especially those experiencing severe pneumonia.

Plain English
This study looked at how factors like income and education level affect survival rates in patients newly diagnosed with multiple myeloma, a type of blood cancer. Researchers analyzed health records from over 122,000 patients and found that marital status and household income at diagnosis negatively influenced survival rates. This matters because understanding these socioeconomic factors can help identify which patients are at higher risk and could lead to better support and treatment options. Who this helps: This helps patients, especially those from lower-income backgrounds.

Plain English
This study looked at how well the drug venetoclax works for patients with multiple myeloma (MM) who have already had many treatments. Among 56 patients treated at the Mayo Clinic, 44% showed a positive response to the drug, with the best results seen in the 42 patients with a specific genetic feature (t(11;14)), leading to longer survival rates compared to those without it. Overall, patients lived an average of 28.4 months after starting venetoclax, and those with t(11;14) lived even longer. Who this helps: This information is valuable for patients with multiple myeloma, especially those with the t(11;14) genetic marker, and their doctors in choosing effective treatments.

Plain English
This study looked at a 54-year-old woman who had a serious allergic reaction after receiving anesthesia that contained benzyl alcohol. Patch tests confirmed her allergy, and when she had surgery again the following year without benzyl alcohol in her anesthesia, she didn't have any allergic reactions. This matters because it highlights the importance of identifying and avoiding certain anesthetics for patients with known allergies to prevent severe reactions. Who this helps: This helps patients with benzyl alcohol allergies and the doctors who treat them.

Plain English
This study looked at how much scientific evidence supports the National Comprehensive Cancer Network's (NCCN) guidelines for treating the most common blood cancers. Out of 1,353 treatment recommendations, only 5% were based on high-quality evidence, though this is an improvement from 3% in 2011. This matters because it highlights that most treatment guidelines rely on expert opinions rather than strong scientific data, indicating a need for more research in this area. Who this helps: Patients with blood cancers and their doctors.

Plain English
This study looked at 144 patients at the Mayo Clinic who have inherited conditions that make them more prone to blood cancers. It found that half of these patients (72) had specific bone marrow failure syndromes, while others had genetic predispositions to different types of cancers. Notably, 91% of patients evaluated showed changes in their treatment plans, including new screenings and referrals for stem cell transplants, emphasizing the critical need for specialized care in managing these patients. Who this helps: This helps patients with inherited cancer risks and their healthcare providers.

Plain English
This study looked at the effectiveness and safety of belantamab mafodotin, a cancer treatment for patients with relapsed multiple myeloma, based on data from 36 patients treated at the Mayo Clinic. Out of these patients, 33% showed a positive response to the treatment, with some achieving significant improvements, but 43% experienced eye problems as a side effect, leading to some patients stopping the treatment. The findings indicate that while belantamab can help a third of the patients, side effects like keratopathy can be significant and need to be managed. Who this helps: This helps patients with relapsed multiple myeloma and their doctors in understanding treatment options and potential side effects.

Plain English
This study looked at how well the drug ibrutinib works for patients with Waldenström macroglobulinaemia (WM) when used outside of clinical trials. The researchers followed 80 patients and found that 91% of them responded to the treatment, with a majority showing a major response. However, 31% of patients stopped taking the drug, mostly because of side effects, and 36% experienced a specific issue (IgM rebound) when they suddenly stopped the treatment. Who this helps: These findings can benefit doctors and patients dealing with WM by providing insights into the effectiveness and challenges of using ibrutinib in real-world settings.

Plain English
This study looked at how a genetic change called MYD88 mutation affects patients with Waldenström macroglobulinemia (WM) when their condition worsens into a more aggressive form of cancer. Out of nearly 1,150 patients, 50 developed high-grade lymphoma, and those with the MYD88 mutation transformed faster, with a 5-year transformation rate of 16% compared to just 2.8% for those without the mutation. The findings highlight the importance of MYD88 status in predicting disease progression and survival, as transformed patients faced significantly higher risks of death. Who this helps: This research benefits doctors and patients with WM by providing insight into the risks associated with MYD88 mutations.

Plain English
This study focused on improving the diagnosis of primary plasma cell leukemia (pPCL) in patients newly diagnosed with multiple myeloma. Researchers found that using a method called multiparametric flow cytometry (MFC) to detect certain levels of plasma cells in the blood was very effective: about 5% of patients had over 200 plasma cells per microliter of blood, identifying them as having pPCL with a 99% accuracy. Patients with this higher level of plasma cells typically had a much shorter time until their next treatment (18 months compared to 30 months) and lower overall survival rates (38 months vs. 70 months). Who this helps: This research benefits doctors and patients by providing a more accurate method for diagnosing pPCL.

Plain English
This study looked at how well people can tell the difference between slight angles using their sense of touch as they experience different stages of cognitive decline related to Alzheimer's disease. Researchers tested 120 individuals, dividing them into four groups: healthy older adults, those with early subjective cognitive decline, those with mild cognitive impairment, and those with Alzheimer's. They found that as cognitive decline progressed, the ability to accurately distinguish angles decreased significantly, showing that tactile discrimination can be a useful early warning sign for Alzheimer's disease. Who this helps: This benefits patients in the early stages of cognitive decline and their doctors, providing a way to detect Alzheimer's sooner.

Plain English
This study looked at the survival rates of patients with light chain amyloidosis who either received stem cell transplants soon after collecting stem cells or delayed the transplant. Researchers found that after following 651 patients, those who had their transplants early lived a median of 13 years, while those who delayed had a median of 11.4 years, showing no significant difference in survival rates between the two groups. This is important because it suggests that patients may not need to rush into a transplant, and further research is needed to determine who should choose each option. Who this helps: Patients with light chain amyloidosis and their healthcare providers.

Plain English
This study looked at how a specific type of training called neurofeedback, which uses brain signals related to sound processing, can improve memory in patients experiencing early signs of cognitive decline, known as subjective cognitive decline (SCD). The researchers trained 17 participants over two weeks and found that those who received the neurofeedback showed better memory performance in difficult tasks that require recalling sounds. This improvement is important because it suggests a potential new way to help people at risk of Alzheimer's disease enhance their cognitive abilities before significant decline happens. Who this helps: Patients experiencing early cognitive decline.

Plain English
This study looked at how focusing on visual tasks affects our ability to remember touch sensations. Researchers found that when people paid more attention to touch while also handling visual tasks, their ability to recognize those touch sensations improved. Specifically, when attention was divided, the brain took longer to respond to touch, showing that our memory for touch decreases if we are distracted by visual information. Who this helps: This helps patients, particularly those with conditions affecting sensory processing or attention.

Plain English
This study focused on three rare orchid species from Peninsular Malaysia that are endangered due to illegal trading. Researchers developed specific markers that can reliably identify each of these orchids, creating three unique genetic identifiers that can help distinguish them from one another. This is important because it can aid in their conservation and help stop illegal sales, ensuring these species don’t go extinct. Who this helps: This benefits conservationists, law enforcement, and anyone working to protect endangered plants.

Plain English
This study looked at how schizophrenia affects the brain's response when patients think about things related to themselves. Researchers tested 18 schizophrenia patients and 18 healthy individuals, finding that patients showed unusual brain activity—specifically, lower alpha wave activity—during tasks related to self-reflection. This matters because it suggests that these brain activity patterns contribute to difficulties with self-referential thinking in schizophrenia patients, which could lead to improvements in treatment strategies. Who this helps: This helps patients with schizophrenia and their doctors.

Plain English
This study looked at how widely a biosimilar drug called filgrastim-sndz (Zarxio) has been used and its costs in two groups: people with commercial insurance and those with Medicare Advantage. By March 2018, filgrastim-sndz made up 47% of filgrastim use among commercially insured patients and 42% among Medicare Advantage patients. The original drug cost 31% more than its biosimilar for commercially insured patients, but the price difference was very small for Medicare Advantage users. Who this helps: This benefits patients who use filgrastim as part of their treatment, especially those in Medicare and commercial insurance.

Plain English
This research paper discusses a 70-year-old woman who initially seemed to have amyloidosis due to symptoms like an enlarged tongue and muscle weakness. However, after further testing, she was diagnosed with Pompe disease, which also explained her symptoms. This finding is important because it shows that two rare diseases can appear similar, highlighting the need for thorough evaluations to ensure patients receive the correct diagnosis. Who this helps: This helps doctors by guiding them in accurately diagnosing patients with complex symptoms.

Plain English
This study looked at the establishment of an epidural pain relief program for women in labor at a public hospital in Georgetown, Guyana, where such services were previously unavailable. After training, 93% of healthcare providers believed that women should have access to epidurals, but within two months, the program faced significant challenges, such as a lack of available anesthesia staff (63%) and insufficient supplies (16%). Ultimately, despite initial enthusiasm and some successful placements, the program was not able to sustain itself. Who this helps: This benefits women giving birth in public hospitals who need pain relief during labor.